Published in

Taylor and Francis Group, OncoImmunology, 6(2), p. e24440

DOI: 10.4161/onci.24440

Links

Tools

Export citation

Search in Google Scholar

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy

Journal article published in 2013 by Gerty Schreibelt, Kalijn F. Bol ORCID, Erik Hjg Aarntzen, Winald R. Gerritsen, Cornelis Ja Punt, I. Jolanda M. de Vries, Carl G. Figdor, I. Jolanda M. de Vries
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Dendritic cell-based anticancer immunotherapy is feasible, safe and results in the induction of tumor-specific immune responses, at least in a fraction of vaccinated patients. The concomitant activation of cytotoxic and helper T cells, by loading DCs with peptides or electroporating them with the corresponding mRNAs, may further enhance vaccine-induced antitumor responses.